Glenmark to launch cancer drug Zanubrutinib in India
Zanubrutinib will be marketed in India under the brand name Brukinsa.
It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.
"We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said.
The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at ₹ 1,600.85 apiece on BSE.
In March, Glenmark Pharmaceuticals had launched a medication for glycemic control and weight-loss for diabetes patients.
The Mumbai-based drug firm launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)''Glempa-L (Empagliflozin 10/25 mg Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg Metformin 500/1000 mg).
The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk.
Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus.
Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation.
"The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes mellitus with established cardiovascular disease more effectively," Glenmark Pharmaceuticals President and Head of India Formulations Business Alok Malik had said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
2 days ago
- Business Standard
Glenmark Pharmaceuticals consolidated net profit declines 86.23% in the June 2025 quarter
Sales decline 5.09% to Rs 3059.33 crore Net profit of Glenmark Pharmaceuticals declined 86.23% to Rs 46.87 crore in the quarter ended June 2025 as against Rs 340.27 crore during the previous quarter ended June 2024. Sales declined 5.09% to Rs 3059.33 crore in the quarter ended June 2025 as against Rs 3223.30 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 3059.333223.30 -5 OPM % 18.9818.25 - PBDT 548.73580.12 -5 PBT 418.81462.33 -9 NP 46.87340.27 -86
&w=3840&q=100)
Business Standard
3 days ago
- Business Standard
Glenmark Q1 profit tanks 86% on US settlement hit; revenue stays flat
Glenmark Pharmaceuticals reported an 86 per cent year-on-year decline in consolidated net profit to ₹46.8 crore for the first quarter of FY26. Revenue from operations rose marginally by 0.6 per cent to ₹3,264 crore. Sequentially, profit jumped 917 per cent, while revenue was up 0.2 per cent. The sharp profit fall was due to a provision of $37.75 million made by Glenmark to settle a US antitrust and consumer protection lawsuit with a putative direct purchaser class, subject to court approval. Excluding this, profit before tax and exceptional expenses stood at ₹418.8 crore, down 9.4 per cent year-on-year compared with ₹462 crore last year. Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, said: 'The recent IGI–AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets while advancing our branded, specialty, and innovative products.' The results were announced after market hours. Glenmark's stock rose 0.6 per cent to end the day at ₹2,043.95 per share on the BSE. The North America business posted revenue of ₹778 crore for the quarter, down 0.3 per cent year-on-year. Sequentially, it recorded 8.9 per cent growth, driven by market share gains in injectable product launches and partnered products. Revenue from emerging markets stood at ₹572.1 crore, marginally higher than ₹570.8 crore in the same period last year, registering a 0.2 per cent year-on-year increase. The company continues to expect double-digit growth on a constant currency basis. In the European market, revenue was ₹667.8 crore compared with ₹695.7 crore in the same period last year, marking a 4 per cent decline.
Business Standard
3 days ago
- Business Standard
Sensex, Nifty extend gains in morning trade; IT shares rally
The key domestic indices traded with moderate gains in the morning trade. Investors will keep an eye on WPI data, scheduled later today. The Nifty scaled above the 24,650 mark. IT shares jumped for fourth consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex advanced 174.37 points or 0.22% to 80,714.28. The Nifty 50 index added 41.50 points or 0.17% to 24,660.70. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index shed 0.02%, while the S&P BSE Small-Cap index fell 0.19%. The market breadth was negative. On the BSE, 1,768 shares rose and 1,812 shares fell. A total of 203 shares were unchanged. Earnings Today: Ashok Leyland (up 0.04%), Glenmark Pharmaceuticals(down 0.01%), Vodafone Idea(down 1.57%), Indian Oil Corporation (IOCL)(down 0.81%), Ahluwalia Contracts (India)(up 1%), Alkyl Amines Chemicals(down 0.92%), Amara Raja Energy & Mobility(down 0.92%), AstraZeneca Pharma India (up 1.18%, Ethos(up 0.56%) , Hindustan Oil Exploration Company (down 0.03%), Inox Green Energy Services,(down 0.48%) will declare their result later today. New Listing: Shares of JSW Cement were currently trading at Rs 151.80 at 10:30 IST on the BSE, representing a premium of 3.27% compared with the issue price of Rs 147. The scrip was listed at Rs 153, exhibiting a premium of 4.08% to the issue price. So far, the stock has hit a high of Rs 154.70 and a low of Rs 150.15. On the BSE, over 60.21 lakh shares of the company were traded in the counter so far. Shares of All Time Plastics were currently trading at at Rs 302.85 at 10:30 IST on the BSE, representing a premium of 10.13% compared with the issue price of Rs 275. The scrip was listed at Rs 314.30, exhibiting a premium of 14.29% to the issue price. So far, the stock has hit a high of Rs 322.15 and a low of Rs 288.10. On the BSE, over 11.62 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty IT index advanced 0.63% to 34,911.35. The index rose 1.49% in the four trading sessions. Infosys (up 1.58%), Wipro (up 1.4%), LTIMindtree (up 0.83%), Mphasis (up 0.28%) and Oracle Financial Services Software (up 0.22%), Coforge (up 0.11%), Persistent Systems (up 0.1%) advanced. Stocks in Spotlight: Engineers India declined 3.26% after the company reported a 28.6% fall in consolidated net profit to Rs 65.40 crore on a 39.5% increase in revenue from operations to Rs 870.36 crore in Q1 FY26 over Q1 FY25. Indian Railway Catering & Tourism Corporation (IRCTC) shed 0.20%. The company reported a 7.47% jump in consolidated net profit to Rs 330.70 crore, while revenue from operations rose 3.76% to Rs 1,159.68 crore in Q1 FY26 over Q1 FY25.
